Bromocriptine Mesylate
Average across 3 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Zydus Lifesciences Limited | unknown | 2 | SUPPLYING |
| ANI Pharmaceuticals, Inc. | unknown | 2 | SUPPLYING |
| Zydus Pharmaceuticals USA Inc. | unknown | 2 | SUPPLYING |
| Mylan Pharmaceuticals Inc. | unknown | 2 | EXITED 2027 |
Shortages, recalls, and registration changes attached to this drug concept.
Failed Impurities/Degradation Specifications: Out of Specification (OOS) result reported for 2- Bromoergine impurity of Bromocriptine Mesylate Capsules. — Recalling firm: Zydus Pharmaceuticals (USA) Inc — Nationwide in the USA
Failed impurities/degradation specifications: Out of specification results noticed in related substance test during analysis of 24 months long term (25 degree Celsius /65% RH) stability samples of two batches. — Recalling firm: Zydus Pharmaceuticals USA Inc — US Nationwide
Pill